<DOC>
	<DOCNO>NCT02739113</DOCNO>
	<brief_summary>Earlier protocol cultivate oral mucosal epithelial transplantation ( COMET ) require trypsin/EDTA isolate epithelial cell tissue , use murine 3T3 cell feeder cell , result biosafety concern . This study use collagenase instead trypsin/EDTA isolate epithelial cell , use 3T3 cell co-culture , make animal ingredient-free cell culture product . The purpose study evaluate feasibility new protocol COMET clinical use .</brief_summary>
	<brief_title>Cultivated Autologous Oral Mucosal Epithelial Transplantation Treatment Ocular Surface Diseases</brief_title>
	<detailed_description>When corneal epithelial stem cell destroy severe trauma burn autoimmune disease , poor regeneration corneal epithelium , persistent inflammatory reaction , neovascular ingrowth , conjunctivalization may ensue , seriously reduce vision . In treat diseased eye , eye healthy , limbal tissue contain corneal epithelial stem cell harvest direct tissue transplantation , ex vivo cultivation expansion several day transplantation . For patient bilaterally damage eye , rejection rate non-HLA match allograft limbal stem cell transplantation high , addition , adverse reaction long-term immunosuppressive therapy may life-threatening . Therefore , 2004 Japanese researcher first propose novel technique treat ocular surface disease use cultivate autologous oral mucosal epithelial transplantation ( COMET ) . From 2006 2009 , investigator also conduct Phase I clinical trial approve Taiwan FDA . In Phase I trial , investigator demonstrate efficacy cell therapy promote wound heal patient severe ocular surface burn ( Ma DHK et al . Eye 2009 ; 23 : 1442- 1450 ) . Investigators also identify long-term persistence transplant oral mucosal epithelial cell cornea ( Chen HCJ et al . Invest Ophthalmol Vis Sci 2009 ; 50:4660-4668 ) , justify innovative surgical procedure effective alternative treatment modality . However , previous protocol , animal product fetal calf serum 3T3 cell culture use , raise biosafety concern . For , recently investigator develop animal ingredient-free cell culture protocol , protocol meet GTP standard , obtain accreditation Taiwan FDA affiliate institute . Therefore , focus current Phase Ib trial confirm feasibility follow item : 1 . To produce cell culture product contain animal ingredient , avoid zoonosis . The oral mucosal epithelial cell thus culture used treat ocular surface disease limbal stem cell deficiency . 2 . To reduce recurrence corneal neovascularization COMET , Bevacizumab ( Avastin ) inject locally , improve corneal transparency visual acuity .</detailed_description>
	<criteria>Severe corneal epithelial deficiency Having favorable prognosis potential Normal intraocular pressure Normal light perception optic nerve No retinal disease inflict eye No severe dry eye Having unfavorable prognosis potential Severe systemic disorder Unable use daily vision Mentally retard execute permit surgery Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>OMECs</keyword>
	<keyword>Cornea</keyword>
	<keyword>Amniotic membrane</keyword>
	<keyword>Collagenase</keyword>
</DOC>